Revenue came in way higher than expected, which is always a good thing. Now folks are starting to look at their actual business, and not just the stock swings, which is major progress. Their partnering with big pharma on antibody discovery could mean real momentum building. Definitely worth keeping an eye on.
There are no replies in this thread yet. Be the first to post a reply below: